drugset / Trial / NCT07215650
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.
Timeline
- Start
- 2025-09-16
- Primary completion
- 2027-12
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cizutamig | Protein / enzyme biologic | — | — |